The DOI matches its Crossref record; 176 of the 176 references it cites were found in a registry or an index.
Dopamine, Oxidative Stress and Protein–Quinone Modifications in Parkinson's and Other Neurodegenerative Diseases
Abstract
Dopamine (DA) is the most important catecholamine in the brain, as it is the most abundant and the precursor of other neurotransmitters. Degeneration of nigrostriatal neurons of substantia nigra pars compacta in Parkinson's disease represents the best‐studied link between DA neurotransmission and neuropathology. Catecholamines are reactive molecules that are handled through complex control and transport systems. Under normal conditions, small amounts of cytosolic DA are converted to neuromelanin in a stepwise process involving melanization of peptides and proteins. However, excessive cytosolic or extraneuronal DA can give rise to nonselective protein modifications. These reactions involve DA oxidation to quinone species and depend on the presence of redox‐active transition metal ions such as iron and copper. Other oxidized DA metabolites likely participate in post‐translational protein modification. Thus, protein–quinone modification is a heterogeneous process involving multiple DA‐derived residues that produce structural and conformational changes of proteins and can lead to aggregation and inactivation of the modified proteins.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
Parkinson's disease: clinical features and diagnosis
Jankovic, J. (2008) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.131045 · Cited by 5,720
Microglia-mediated neurotoxicity: uncovering the molecular mechanisms
Block, M. L., Zecca, L., & Hong, J.-S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2038 · Cited by 4,110
Self-citationThe role of iron and reactive oxygen species in cell death
Dixon, S. J., & Stockwell, B. R. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1416 · Cited by 2,381
Ehringer, H., & Hornykiewicz, O. (1960) · Klinische Wochenschrift · doi:10.1007/bf01485901 · Cited by 1,867
The locus coeruleus and noradrenergic modulation of cognition
Sara, S. J. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2573 · Cited by 1,848
Levodopa and the Progression of Parkinson's Disease
(2004) · New England Journal of Medicine · doi:10.1056/nejmoa033447 · Cited by 1,821
The role of iron in brain ageing and neurodegenerative disorders
Ward, R. J., Zucca, F. A., Duyn, J. H., Crichton, R. R., & Zecca, L. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70117-6 · Cited by 1,819
Self-citationIron, brain ageing and neurodegenerative disorders
Zecca, L., Youdim, M. B. H., Riederer, P., Connor, J. R., & Crichton, R. R. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1537 · Cited by 1,801
Self-citationCopper Active Sites in Biology
Solomon, E. I., Heppner, D. E., Johnston, E. M., Ginsbach, J. W., Cirera, J., Qayyum, M., Kieber-Emmons, M. T., Kjaergaard, C. H., Hadt, R. G., & Tian, L. (2014) · Chemical Reviews · doi:10.1021/cr400327t · Cited by 1,751
Mazzulli, J. R., Xu, Y.-H., Sun, Y., Knight, A. L., McLean, P. J., Caldwell, G. A., Sidransky, E., Grabowski, G. A., & Krainc, D. (2011) · Cell · doi:10.1016/j.cell.2011.06.001 · Cited by 1,341
Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease
Hirsch, E., Graybiel, A. M., & Agid, Y. A. (1988) · Nature · doi:10.1038/334345a0 · Cited by 1,301
Pathogenesis of parkinson's disease: dopamine, vesicles and α-synuclein
Lotharius, J., & Brundin, P. (2002) · Nature Reviews Neuroscience · doi:10.1038/nrn983 · Cited by 1,283
13 reasons why the brain is susceptible to oxidative stress
Cobley, J. N., Fiorello, M. L., & Bailey, D. M. (2018) · Redox Biology · doi:10.1016/j.redox.2018.01.008 · Cited by 1,215
Dysregulation of the dopamine system in the pathophysiology of schizophrenia and depression
Grace, A. A. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2016.57 · Cited by 1,166
Dexter, D. T., Wells, F. R., Lee, A. J., Agid, F., Agid, Y., Jenner, P., & Marsden, C. D. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb07264.x · Cited by 1,149
Kinetic Stabilization of the α-Synuclein Protofibril by a Dopamine-α-Synuclein Adduct
Conway, K. A., Rochet, J.-C., Bieganski, R. M., & Lansbury, P. T. (2001) · Science · doi:10.1126/science.1063522 · Cited by 1,127
Selective neuronal vulnerability in Parkinson disease
Surmeier, D. J., Obeso, J. A., & Halliday, G. M. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2016.178 · Cited by 1,116
Tyrosine hydroxylase and regulation of dopamine synthesis
Daubner, S. C., Le, T., & Wang, S. (2011) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2010.12.017 · Cited by 1,092
Catecholamine Metabolism: A Contemporary View with Implications for Physiology and Medicine
Eisenhofer, G., Kopin, I. J., & Goldstein, D. S. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.3.1 · Cited by 1,072
The physical and chemical properties of eumelanin
Meredith, P., & Sarna, T. (2006) · Pigment Cell Research · doi:10.1111/j.1600-0749.2006.00345.x · Cited by 1,033
Zarow, C., Lyness, S. A., Mortimer, J. A., & Chui, H. C. (2003) · Archives of Neurology · doi:10.1001/archneur.60.3.337 · Cited by 1,002
Increased nigral iron content in postmortem parkinsonian brain
Dexter, D. T., Wells, F. R., Agid, F., Agid, Y., Lees, A. J., Jenner, P., & Marsden, C. D. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91361-4 · Cited by 963
Berke, J. D. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0152-y · Cited by 904
‘Rejuvenation’ protects neurons in mouse models of Parkinson’s disease
Chan, C. S., Guzman, J. N., Ilijic, E., Mercer, J. N., Rick, C., Tkatch, T., Meredith, G. E., & Surmeier, D. J. (2007) · Nature · doi:10.1038/nature05865 · Cited by 904
Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson’s disease
Burbulla, L. F., Song, P., Mazzulli, J. R., Zampese, E., Wong, Y. C., Jeon, S., Santos, D. P., Blanz, J., Obermaier, C. D., Strojny, C., et al. (2017) · Science · doi:10.1126/science.aam9080 · Cited by 874
Structural disorder of monomeric α-synuclein persists in mammalian cells
Theillet, F.-X., Binolfi, A., Bekei, B., Martorana, A., Rose, H. M., Stuiver, M., Verzini, S., Lorenz, D., van Rossum, M., Goldfarb, D., et al. (2016) · Nature · doi:10.1038/nature16531 · Cited by 868
The Ubiquitin Code in the Ubiquitin-Proteasome System and Autophagy
Kwon, Y. T., & Ciechanover, A. (2017) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2017.09.002 · Cited by 817
Dopamine covalently modifies and functionally inactivates parkin
LaVoie, M. J., Ostaszewski, B. L., Weihofen, A., Schlossmacher, M. G., & Selkoe, D. J. (2005) · Nature Medicine · doi:10.1038/nm1314 · Cited by 722
Parkinson disease: from pathology to molecular disease mechanisms
Dexter, D. T., & Jenner, P. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.01.018 · Cited by 707
Pathology of Parkinson’s disease: Changes other than the nigrostriatal pathway
Jellinger, K. A. (1991) · Molecular and Chemical Neuropathology · doi:10.1007/bf03159935 · Cited by 684
Swerdlow, N. R., & Koob, G. F. (1987) · Behavioral and Brain Sciences · doi:10.1017/s0140525x00047488 · Cited by 674
Polydopamine and Eumelanin: From Structure–Property Relationships to a Unified Tailoring Strategy
d’Ischia, M., Napolitano, A., Ball, V., Chen, C.-T., & Buehler, M. J. (2014) · Accounts of Chemical Research · doi:10.1021/ar500273y · Cited by 668
Complexity of dopamine metabolism
Meiser, J., Weindl, D., & Hiller, K. (2013) · Cell Communication and Signaling · doi:10.1186/1478-811x-11-34 · Cited by 663
Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease
Zucca, F. A., Segura-Aguilar, J., Ferrari, E., Muñoz, P., Paris, I., Sulzer, D., Sarna, T., Casella, L., & Zecca, L. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.09.012 · Cited by 659
Self-citationBiochemistry of Peroxynitrite and Protein Tyrosine Nitration
Ferrer-Sueta, G., Campolo, N., Trujillo, M., Bartesaghi, S., Carballal, S., Romero, N., Alvarez, B., & Radi, R. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00568 · Cited by 640
On the Presence of 3-Hydroxytyramine in Brain
CARLSSON, A., LINDQVIST, M., MAGNUSSON, T., & WALDECK, B. (1958) · Science · doi:10.1126/science.127.3296.471 · Cited by 634
Jiang, T., Sun, Q., & Chen, S. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.07.005 · Cited by 586
Mosharov, E. V., Larsen, K. E., Kanter, E., Phillips, K. A., Wilson, K., Schmitz, Y., Krantz, D. E., Kobayashi, K., Edwards, R. H., & Sulzer, D. (2009) · Neuron · doi:10.1016/j.neuron.2009.01.033 · Cited by 534
Self-citationα-Synuclein: Membrane Interactions and Toxicity in Parkinson's Disease
Auluck, P. K., Caraveo, G., & Lindquist, S. (2010) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.042308.113313 · Cited by 519
A Chemist's View of Melanogenesis
Ito, S. (2003) · Pigment Cell Research · doi:10.1034/j.1600-0749.2003.00037.x · Cited by 508
Protective and toxic roles of dopamine in Parkinson's disease
Segura‐Aguilar, J., Paris, I., Muñoz, P., Ferrari, E., Zecca, L., & Zucca, F. A. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12686 · Cited by 498
Self-citationBiological metals and metal-targeting compounds in major neurodegenerative diseases
Barnham, K. J., & Bush, A. I. (2014) · Chem. Soc. Rev. · doi:10.1039/c4cs00138a · Cited by 497
Zecca, L., Stroppolo, A., Gatti, A., Tampellini, D., Toscani, M., Gallorini, M., Giaveri, G., Arosio, P., Santambrogio, P., Fariello, R. G., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403495101 · Cited by 495
Self-citationMelanins and melanogenesis: Methods, standards, protocols
d'Ischia, M., Wakamatsu, K., Napolitano, A., Briganti, S., Garcia‐Borron, J., Kovacs, D., Meredith, P., Pezzella, A., Picardo, M., Sarna, T., et al. (2013) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12121 · Cited by 484
DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase
Andres-Mateos, E., Perier, C., Zhang, L., Blanchard-Fillion, B., Greco, T. M., Thomas, B., Ko, H. S., Sasaki, M., Ischiropoulos, H., Przedborski, S., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703219104 · Cited by 479
Redish, A. D. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2015.30 · Cited by 479
Defects in trafficking bridge Parkinson’s disease pathology and genetics
Abeliovich, A., & Gitler, A. D. (2016) · Nature · doi:10.1038/nature20414 · Cited by 462
Neurotransmitter and psychostimulant recognition by the dopamine transporter
Wang, K. H., Penmatsa, A., & Gouaux, E. (2015) · Nature · doi:10.1038/nature14431 · Cited by 425
Theofilas, P., Ehrenberg, A. J., Dunlop, S., Di Lorenzo Alho, A. T., Nguy, A., Leite, R. E. P., Rodriguez, R. D., Mejia, M. B., Suemoto, C. K., Ferretti-Rebustini, R. E. D. L., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.06.2362 · Cited by 416
Potential oxidative pathways of brain catecholamines
Tse, D. C. S., McCreery, R. L., & Adams, R. N. (1976) · Journal of Medicinal Chemistry · doi:10.1021/jm00223a008 · Cited by 415
Larsen, K. E., Schmitz, Y., Troyer, M. D., Mosharov, E., Dietrich, P., Quazi, A. Z., Savalle, M., Nemani, V., Chaudhry, F. A., Edwards, R. H., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.3821-06.2006 · Cited by 415
Self-citationOn Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease
Giguère, N., Burke Nanni, S., & Trudeau, L.-E. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00455 · Cited by 413
Dopaminergic dysfunction in schizophrenia: Salience attribution revisited
Heinz, A., & Schlagenhauf, F. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq031 · Cited by 412
Sulzer, D., Bogulavsky, J., Larsen, K. E., Behr, G., Karatekin, E., Kleinman, M. H., Turro, N., Krantz, D., Edwards, R. H., Greene, L. A., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.22.11869 · Cited by 407
Self-citationStriatal dopamine neurotransmission: Regulation of release and uptake
Sulzer, D., Cragg, S. J., & Rice, M. E. (2016) · Basal Ganglia · doi:10.1016/j.baga.2016.02.001 · Cited by 382
Self-citationCurrent and experimental treatments of Parkinson disease: A guide for neuroscientists
Oertel, W., & Schulz, J. B. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13750 · Cited by 369
Lysine Acetylation Goes Global: From Epigenetics to Metabolism and Therapeutics
Ali, I., Conrad, R. J., Verdin, E., & Ott, M. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00181 · Cited by 366
The place of dopamine in the cortico-basal ganglia circuit
Haber, S. N. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.10.008 · Cited by 364
Deas, E., Cremades, N., Angelova, P. R., Ludtmann, M. H. R., Yao, Z., Chen, S., Horrocks, M. H., Banushi, B., Little, D., Devine, M. J., et al. (2016) · Antioxidants & Redox Signaling · doi:10.1089/ars.2015.6343 · Cited by 360
Enzymatic Oxidation of Dopamine: The Role of Prostaglandin H Synthase
Hastings, T. G. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.64020919.x · Cited by 359
Song, Y., & Buettner, G. R. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.05.009 · Cited by 359
Effect of Mutant α-Synuclein on Dopamine Homeostasis in a New Human Mesencephalic Cell Line
Lotharius, J., Barg, S., Wiekop, P., Lundberg, C., Raymon, H. K., & Brundin, P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205518200 · Cited by 352
Cilia, R., Akpalu, A., Sarfo, F. S., Cham, M., Amboni, M., Cereda, E., Fabbri, M., Adjei, P., Akassi, J., Bonetti, A., et al. (2014) · Brain · doi:10.1093/brain/awu195 · Cited by 339
Role of α-Synuclein in Presynaptic Dopamine Recruitment
Yavich, L., Tanila, H., Vepsäläinen, S., & Jäkälä, P. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.2559-04.2004 · Cited by 316
Kinetic and Structural Analysis of the Early Oxidation Products of Dopamine
Bisaglia, M., Mammi, S., & Bubacco, L. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610893200 · Cited by 303
Zecca, L., Fariello, R., Riederer, P., Sulzer, D., Gatti, A., & Tampellini, D. (2002) · FEBS Letters · doi:10.1016/s0014-5793(01)03269-0 · Cited by 285
Self-citationMarchitti, S. A., Deitrich, R. A., & Vasiliou, V. (2007) · Pharmacological Reviews · doi:10.1124/pr.59.2.1 · Cited by 280
α-synuclein interacts with PrPC to induce cognitive impairment through mGluR5 and NMDAR2B
Ferreira, D. G., Temido-Ferreira, M., Vicente Miranda, H., Batalha, V. L., Coelho, J. E., Szegö, É. M., Marques-Morgado, I., Vaz, S. H., Rhee, J. S., Schmitz, M., et al. (2017) · Nature Neuroscience · doi:10.1038/nn.4648 · Cited by 278
“Is dopamine involved in Alzheimer's disease?â€
Martorana, A., & Koch, G. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00252 · Cited by 275
Norris, E. H., Giasson, B. I., Hodara, R., Xu, S., Trojanowski, J. Q., Ischiropoulos, H., & Lee, V. M.-Y. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m412621200 · Cited by 273
Sulzer, D., Cassidy, C., Horga, G., Kang, U. J., Fahn, S., Casella, L., Pezzoli, G., Langley, J., Hu, X. P., Zucca, F. A., et al. (2018) · npj Parkinson's Disease · doi:10.1038/s41531-018-0047-3 · Cited by 270
Self-citationLotharius, J. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.20.2395 · Cited by 269
Sequestration of iron by Lewy bodies in Parkinson's disease
Castellani, R. J., Siedlak, S. L., Perry, G., & Smith, M. A. (2000) · Acta Neuropathologica · doi:10.1007/s004010050001 · Cited by 265
Protein degradation pathways in Parkinson’s disease: curse or blessing
Ebrahimi-Fakhari, D., Wahlster, L., & McLean, P. J. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1004-6 · Cited by 253
Brain iron metabolism and its perturbation in neurological diseases
Crichton, R. R., Dexter, D. T., & Ward, R. J. (2011) · Journal of Neural Transmission · doi:10.1007/s00702-010-0470-z · Cited by 248
Copper pathology in vulnerable brain regions in Parkinson's disease
Davies, K. M., Bohic, S., Carmona, A., Ortega, R., Cottam, V., Hare, D. J., Finberg, J. P. M., Reyes, S., Halliday, G. M., Mercer, J. F. B., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.09.034 · Cited by 244
Neuromelanin of the Human Substantia Nigra: An Update
Zucca, F. A., Basso, E., Cupaioli, F. A., Ferrari, E., Sulzer, D., Casella, L., & Zecca, L. (2014) · Neurotoxicity Research · doi:10.1007/s12640-013-9435-y · Cited by 243
Self-citationAggregation of α-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine
Burke, W. J., Kumar, V. B., Pandey, N., Panneton, W. M., Gan, Q., Franko, M. W., O’Dell, M., Li, S. W., Pan, Y., Chung, H. D., et al. (2008) · Acta Neuropathologica · doi:10.1007/s00401-007-0303-9 · Cited by 243
Dopamine Receptors and Neurodegeneration
Claudia, R., Israel, C., & Benjamín, F. (2015) · Aging and disease · doi:10.14336/ad.2015.0330 · Cited by 241
Zecca, L., Bellei, C., Costi, P., Albertini, A., Monzani, E., Casella, L., Gallorini, M., Bergamaschi, L., Moscatelli, A., Turro, N. J., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808768105 · Cited by 240
Spontaneous autoxidation of dopamine
Herlinger, E., Jameson, R. F., & Linert, W. (1995) · Journal of the Chemical Society, Perkin Transactions 2 · doi:10.1039/p29950000259 · Cited by 227
Dopamine induces soluble α-synuclein oligomers and nigrostriatal degeneration
Mor, D. E., Tsika, E., Mazzulli, J. R., Gould, N. S., Kim, H., Daniels, M. J., Doshi, S., Gupta, P., Grossman, J. L., Tan, V. X., et al. (2017) · Nature Neuroscience · doi:10.1038/nn.4641 · Cited by 217
Cellular management of iron in the brain
Connor, J. R., & Menzies, S. L. (1995) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(95)00206-h · Cited by 213
Rubí, B., & Maechler, P. (2010) · Endocrinology · doi:10.1210/en.2010-0745 · Cited by 207
Iron(II) Binding to Amyloid-β, the Alzheimer’s Peptide
Bousejra-ElGarah, F., Bijani, C., Coppel, Y., Faller, P., & Hureau, C. (2011) · Inorganic Chemistry · doi:10.1021/ic201233b · Cited by 198
Interaction of neuromelanin and iron in substantia nigra and other areas of human brain
Zecca, L., Shima, T., Stroppolo, A., Goj, C., Battiston, G. A., Gerbasi, R., Sarna, T., & Swartz, H. M. (1996) · Neuroscience · doi:10.1016/0306-4522(96)00047-4 · Cited by 196
Self-citationReaction of oxidized dopamine with endogenous cysteine residues in the human dopamine transporter
Whitehead, R. E., Ferrer, J. V., Javitch, J. A., & Justice, J. B. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00125.x · Cited by 194
Sulzer, D., Mosharov, E., Talloczy, Z., Zucca, F. A., Simon, J. D., & Zecca, L. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05385.x · Cited by 191
Self-citationEriksen, J., Jørgensen, T. N., & Gether, U. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06599.x · Cited by 175
Yap, T. L., Gruschus, J. M., Velayati, A., Westbroek, W., Goldin, E., Moaven, N., Sidransky, E., & Lee, J. C. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.237859 · Cited by 174
Betts, M. J., Cardenas-Blanco, A., Kanowski, M., Jessen, F., & Düzel, E. (2017) · NeuroImage · doi:10.1016/j.neuroimage.2017.09.042 · Cited by 173
The structure of neuromelanin as studied by chemical degradative methods
Wakamatsu, K., Fujikawa, K., Zucca, F. A., Zecca, L., & Ito, S. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01917.x · Cited by 172
Self-citationTelling, N. D., Everett, J., Collingwood, J. F., Dobson, J., van der Laan, G., Gallagher, J. J., Wang, J., & Hitchcock, A. P. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.07.014 · Cited by 169
Zucca, F. A., Vanna, R., Cupaioli, F. A., Bellei, C., Palma, A. D., Silvestre, D. D., Mauri, P., Grassi, S., Prinetti, A., Casella, L., et al. (2018) · npj Parkinson s Disease · doi:10.1038/s41531-018-0050-8 · Cited by 167
Self-citationα-Synuclein Overexpression Increases Cytosolic Catecholamine Concentration
Mosharov, E. V., Staal, R. G. W., Bové, J., Prou, D., Hananiya, A., Markov, D., Poulsen, N., Larsen, K. E., Moore, C. M. H., Troyer, M. D., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.0519-06.2006 · Cited by 165
Goldstein, D. S., Kopin, I. J., & Sharabi, Y. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.06.006 · Cited by 165
Contrast mechanisms associated with neuromelanin‐MRI
Trujillo, P., Summers, P. E., Ferrari, E., Zucca, F. A., Sturini, M., Mainardi, L. T., Cerutti, S., Smith, A. K., Smith, S. A., Zecca, L., et al. (2016) · Magnetic Resonance in Medicine · doi:10.1002/mrm.26584 · Cited by 164
Self-citationHigh-resolution in vivo imaging of human locus coeruleus by magnetization transfer MRI at 3T and 7T
Priovoulos, N., Jacobs, H. I. L., Ivanov, D., Uludağ, K., Verhey, F. R. J., & Poser, B. A. (2018) · NeuroImage · doi:10.1016/j.neuroimage.2017.07.045 · Cited by 160
Laar, V. S. V., Mishizen-Eberz, A. J., Cascio, M., & Hastings, T. G. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.03.004 · Cited by 154
Oxidation Chemistry of Catecholamines and Neuronal Degeneration: An Update
Napolitano, A., Manini, P., & d’Ischia, M. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711795496863 · Cited by 153
α-Synuclein and Mitochondria: Partners in Crime?
Nakamura, K. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0182-9 · Cited by 149
Bioinorganic chemistry of copper coordination to alpha-synuclein: Relevance to Parkinson's disease
Binolfi, A., Quintanar, L., Bertoncini, C. W., Griesinger, C., & Fernández, C. O. (2012) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2012.05.004 · Cited by 147
Shima, T., Sarna, T., Swartz, H. M., Stroppolo, A., Gerbasi, R., & Zecca, L. (1997) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(96)00623-5 · Cited by 146
Self-citationDopamine-modified α-synuclein blocks chaperone-mediated autophagy
Martinez-Vicente, M., Talloczy, Z., Kaushik, S., Massey, A. C., Mazzulli, J., Mosharov, E. V., Hodara, R., Fredenburg, R., Wu, D.-C., Follenzi, A., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci32806 · Cited by 144
Self-citationIntracellular Patch Electrochemistry: Regulation of Cytosolic Catecholamines in Chromaffin Cells
Mosharov, E. V., Gong, L., Khanna, B., Sulzer, D., & Lindau, M. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-13-05835.2003 · Cited by 143
Self-citationMembrane transporters as mediators of synaptic dopamine dynamics: implications for disease
Lohr, K. M., Masoud, S. T., Salahpour, A., & Miller, G. W. (2016) · European Journal of Neuroscience · doi:10.1111/ejn.13357 · Cited by 140
Genoud, S., Roberts, B. R., Gunn, A. P., Halliday, G. M., Lewis, S. J. G., Ball, H. J., Hare, D. J., & Double, K. L. (2017) · Metallomics · doi:10.1039/c7mt00244k · Cited by 140
Herrera, A., Muñoz, P., Steinbusch, H. W. M., & Segura‐Aguilar, J. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00034 · Cited by 139
Zucca, F. A., Bellei, C., Giannelli, S. G., Terreni, M., Gallorini, M., Rizzio, E., Pezzoli, G., Albertini, A., & Zecca, L. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-006-0453-2 · Cited by 138
Self-citationDOPAL derived alpha-synuclein oligomers impair synaptic vesicles physiological function
Plotegher, N., Berti, G., Ferrari, E., Tessari, I., Zanetti, M., Lunelli, L., Greggio, E., Bisaglia, M., Veronesi, M., Girotto, S., et al. (2017) · Scientific Reports · doi:10.1038/srep40699 · Cited by 133
Self-citationButters, T. D. (2007) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2007.05.035 · Cited by 131
Cu(II)-catalyzed oxidation of dopamine in aqueous solutions: Mechanism and kinetics
Pham, A. N., & Waite, T. D. (2014) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2014.03.018 · Cited by 129
The crystal structure of human dopamine β-hydroxylase at 2.9 Å resolution
Vendelboe, T. V., Harris, P., Zhao, Y., Walter, T. S., Harlos, K., El Omari, K., & Christensen, H. E. M. (2016) · Science Advances · doi:10.1126/sciadv.1500980 · Cited by 125
Dopamine miracle: From brain homogenate to dopamine replacement
Hornykiewicz, O. (2002) · Movement Disorders · doi:10.1002/mds.10115 · Cited by 122
Lu, Y., Prudent, M., Fauvet, B., Lashuel, H. A., & Girault, H. H. (2011) · ACS Chemical Neuroscience · doi:10.1021/cn200074d · Cited by 122
Monoranu, C. M., Apfelbacher, M., Grünblatt, E., Puppe, B., Alafuzoff, I., Ferrer, I., Al‐Saraj, S., Keyvani, K., Schmitt, A., Falkai, P., et al. (2009) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2008.01003a.x · Cited by 121
Rees, J. N., Florang, V. R., Eckert, L. L., & Doorn, J. A. (2009) · Chemical Research in Toxicology · doi:10.1021/tx9000557 · Cited by 121
Peng, Y., Wang, C., Xu, H. H., Liu, Y., & Zhou, F. (2009) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2009.11.005 · Cited by 119
Liang, C., Nelson, O. L., Yazdani, U., Pasbakhsh, P., & German, D. C. (2004) · The Journal of Comparative Neurology · doi:10.1002/cne.20098 · Cited by 117
Glucocerebrosidase mutations and the pathogenesis of Parkinson disease
Beavan, M. S., & Schapira, A. H. V. (2013) · Annals of Medicine · doi:10.3109/07853890.2013.849003 · Cited by 115
Follmer, C., Coelho-Cerqueira, E., Yatabe-Franco, D. Y., Araujo, G. D. T., Pinheiro, A. S., Domont, G. B., & Eliezer, D. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.686584 · Cited by 115
Formation of dopamine-mediated α-synuclein-soluble oligomers requires methionine oxidation
Leong, S. L., Pham, C. L. L., Galatis, D., Fodero‐Tavoletti, M. T., Perez, K. A., Hill, A. F., Masters, C. L., Ali, F. E. A., Barnham, K. J., & Cappai, R. (2009) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.02.009 · Cited by 114
Li, H., & Dryhurst, G. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69041530.x · Cited by 109
Cytochrome P450 mediates dopamine formation in the brainin vivo
Bromek, E., Haduch, A., Gołembiowska, K., & Daniel, W. A. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07339.x · Cited by 104
Mazzulli, J. R., Armakola, M., Bridi, M., Parastatidis, I., & Ischiropoulos, H. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704737200 · Cited by 101
Levodopa: Effect on cell death and the natural history of Parkinson's disease
Olanow, C. W. (2014) · Movement Disorders · doi:10.1002/mds.26119 · Cited by 99
Szot, P. (2012) · Epilepsia · doi:10.1111/j.1528-1167.2012.03476.x · Cited by 97
Dopamine quinones interact with α-synuclein to form unstructured adducts
Bisaglia, M., Tosatto, L., Munari, F., Tessari, I., de Laureto, P. P., Mammi, S., & Bubacco, L. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.03.044 · Cited by 95
Nam, E., Derrick, J. S., Lee, S., Kang, J., Han, J., Lee, S. J. C., Chung, S. W., & Lim, M. H. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00122 · Cited by 89
Bisaglia, M., Soriano, M. E., Arduini, I., Mammi, S., & Bubacco, L. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.06.006 · Cited by 88
Parkin function in Parkinson's disease
Arkinson, C., & Walden, H. (2018) · Science · doi:10.1126/science.aar6606 · Cited by 87
Duce, J. A., Wong, B. X. W., Durham, H., Devedjian, J.-C., Smith, D. P., & Devos, D. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0186-8 · Cited by 81
Kawahara, M., Kato-Negishi, M., & Tanaka, K. (2017) · Metallomics · doi:10.1039/c7mt00046d · Cited by 80
DT-Diaphorase Prevents Aminochrome-Induced Alpha-Synuclein Oligomer Formation and Neurotoxicity
Muñoz, P., Cárdenas, S., Huenchuguala, S., Briceño, A., Couve, E., Paris, I. B., & Segura‐Aguilar, J. (2015) · Toxicological Sciences · doi:10.1093/toxsci/kfv016 · Cited by 80
Thomas, D. M., Francescutti, D. M., & Kuhn, D. M. (2005) · The FASEB Journal · doi:10.1096/fj.05-4873fje · Cited by 80
Presynaptic effects of levodopa and their possible role in dyskinesia
Mosharov, E. V., Borgkvist, A., & Sulzer, D. (2014) · Movement Disorders · doi:10.1002/mds.26103 · Cited by 79
Self-citationEngelen, M., Vanna, R., Bellei, C., Zucca, F. A., Wakamatsu, K., Monzani, E., Ito, S., Casella, L., & Zecca, L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048490 · Cited by 79
Self-citationInsights into the structural biology of Gaucher disease
Smith, L., Mullin, S., & Schapira, A. H. V. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.09.010 · Cited by 79
Wakamatsu, K., Tabuchi, K., Ojika, M., Zucca, F. A., Zecca, L., & Ito, S. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13237 · Cited by 76
Self-citationGirotto, S., Sturlese, M., Bellanda, M., Tessari, I., Cappellini, R., Bisaglia, M., Bubacco, L., & Mammi, S. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.311589 · Cited by 74
Natale, G. D., Ösz, K., Nagy, Z., Sanna, D., Micera, G., Pappalardo, G., Sóvágó, I., & Rizzarell, E. (2009) · Inorganic Chemistry · doi:10.1021/ic802190v · Cited by 74
Sun, Y., Pham, A. N., & Waite, T. D. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13615 · Cited by 70
Ito, S., & Wakamatsu, K. (2006) · Wiley eBooks · doi:10.1002/9780470987100.ch15 · Cited by 66
Convergence of biological nitration and nitrosation via symmetrical nitrous anhydride
Vitturi, D. A., Minarrieta, L., Salvatore, S. R., Postlethwait, E. M., Fazzari, M., Ferrer-Sueta, G., Lancaster, J. R., Freeman, B. A., & Schopfer, F. J. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1814 · Cited by 65
Zhou, W., Gallagher, A., Hong, D.-P., Long, C., Fink, A. L., & Uversky, V. N. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2009.03.053 · Cited by 59
Werner‐Allen, J. W., DuMond, J. F., Levine, R. L., & Bax, A. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201600277 · Cited by 58
Amyloid β and neuromelanin—Toxic or protective molecules?The cellular context makes the difference
Rao, K. S. J., Hegde, M. L., Anitha, S., Musicco, M., Zucca, F. A., TURRO, N. J., & Zecca, L. (2006) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2006.03.004 · Cited by 57
Self-citationDopamine complexes of iron in the etiology and pathogenesis of Parkinson’s disease
ARREGUIN, S., NELSON, P., PADWAY, S., SHIRAZI, M., & PIERPONT, C. (2009) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2008.09.007 · Cited by 55
Metal-Catalyzed Oxidation of Protein-Bound Dopamine
Akagawa, M., Ishii, Y., Ishii, T., Shibata, T., Yotsu‐Yamashita, M., Suyama, K., & Uchida, K. (2006) · Biochemistry · doi:10.1021/bi0614434 · Cited by 55
Chemical Approaches to Investigate Labile Peptide and Protein Phosphorylation
Hauser, A., Penkert, M., & Hackenberger, C. P. R. (2017) · Accounts of Chemical Research · doi:10.1021/acs.accounts.7b00170 · Cited by 55
Reactivity of copper–α-synuclein peptide complexes relevant to Parkinson’s disease
Dell’Acqua, S., Pirota, V., Anzani, C., Rocco, M. M., Nicolis, S., Valensin, D., Monzani, E., & Casella, L. (2015) · Metallomics · doi:10.1039/c4mt00345d · Cited by 52
Self-citationEnzymatic dopamine peroxidation in substantia nigra of human brain
Galzigna, L., Iuliis, A. D., & Zanatta, L. (2000) · Clinica Chimica Acta · doi:10.1016/s0009-8981(00)00313-2 · Cited by 51
Ganzinger, K. A., Narayan, P. S., Qamar, S., Weimann, L., Ranasinghe, R. T., Aguzzi, A., Dobson, C. M., McColl, J. T., George‐Hyslop, P. S., & Klenerman, D. (2014) · ChemBioChem · doi:10.1002/cbic.201402377 · Cited by 50
Ferrari, E., Capucciati, A., Prada, I., Zucca, F. A., D’Arrigo, G., Pontiroli, D., Bridelli, M. G., Sturini, M., Bubacco, L., Monzani, E., et al. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00231 · Cited by 49
Self-citationBioinorganic Life and Neural Activity: Toward a Chemistry of Consciousness?
Chang, C. J. (2017) · Accounts of Chemical Research · doi:10.1021/acs.accounts.6b00531 · Cited by 48
Copper(I/II), α/β‐Synuclein and Amyloid‐β: Menage à Trois?
Ricco, R. D., Valensin, D., Dell’Acqua, S., Casella, L., Hureau, C., & Faller, P. (2015) · ChemBioChem · doi:10.1002/cbic.201500425 · Cited by 46
Self-citationAldehyde dehydrogenase 2 is associated with cognitive functions in patients with Parkinson’s disease
Yu, R., Tan, C., Lu, Y.-C., & Wu, R. (2016) · Scientific Reports · doi:10.1038/srep30424 · Cited by 43
Nakaso, K., Tajima, N., Ito, S., Teraoka, M., Yamashita, A., Horikoshi, Y., Kikuchi, D., Mochida, S., Nakashima, K., & Matsura, T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055068 · Cited by 42
Biophysical groundwork as a hinge to unravel the biology of α-synuclein aggregation and toxicity
Plotegher, N., Greggio, E., Bisaglia, M., & Bubacco, L. (2014) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583513000097 · Cited by 40
Tiiman, A., Luo, J., Wallin, C., Olsson, L., Lindgren, J., Jarvet, J., Roos, P. M., Sholts, S. B., Rahimipour, S., Abrahams, J. P., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160427 · Cited by 39
Ferrari, E., Engelen, M., Monzani, E., Sturini, M., Girotto, S., Bubacco, L., Zecca, L., & Casella, L. (2012) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-012-0951-7 · Cited by 38
Self-citationDetection of Free and Protein-Bound ortho -Quinones by Near-Infrared Fluorescence
Mazzulli, J. R., Burbulla, L. F., Krainc, D., & Ischiropoulos, H. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.5b04420 · Cited by 34
Copper‐Aβ Peptides and Oxidation of Catecholic Substrates: Reactivity and Endogenous Peptide Damage
Pirota, V., Dell’Acqua, S., Monzani, E., Nicolis, S., & Casella, L. (2016) · Chemistry - A European Journal · doi:10.1002/chem.201603824 · Cited by 34
Self-citationThe workings of ferritin: a crossroad of opinions
Hagen, W. R., Hagedoorn, P., & Ebrahimi, K. H. (2017) · Metallomics · doi:10.1039/c7mt00124j · Cited by 34
Myoglobin Modification by Enzyme‐Generated Dopamine Reactive Species
Nicolis, S., Zucchelli, M., Monzani, E., & Casella, L. (2008) · Chemistry - A European Journal · doi:10.1002/chem.200801014 · Cited by 29
Self-citationDell’Acqua, S., Pirota, V., Monzani, E., Camponeschi, F., Ricco, R. D., Valensin, D., & Casella, L. (2016) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.6b00641 · Cited by 27
Self-citationIn vivo protein targets for increased quinoprotein adduct formation in aged substantia nigra
Yu, G., Liu, H., Zhou, W. P., Zhu, X., Yu, C. Y., Wang, N., Zhang, Y., Ma, J., Zhao, Y., Xu, Y., et al. (2015) · Experimental Neurology · doi:10.1016/j.expneurol.2015.04.019 · Cited by 26
Dopamine induces the accumulation of insoluble prion protein and affects autophagic flux
da Luz, M. H. M., Peres, I. T., Santos, T. G., Martins, V. R., Icimoto, M. Y., & Lee, K. S. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00012 · Cited by 26
Wahed, M. G. A. E., & Ayad©, M. (1984) · Analytical Letters · doi:10.1080/00032718408065279 · Cited by 26
Neuroglobin Modification by Reactive Quinone Species
Nicolis, S., Monzani, E., Pezzella, A., Ascenzi, P., Sbardella, D., & Casella, L. (2013) · Chemical Research in Toxicology · doi:10.1021/tx4001896 · Cited by 26
Self-citationWakamatsu, K., Tanaka, H., Tabuchi, K., Ojika, M., Zucca, F. A., Zecca, L., & Ito, S. (2014) · Molecules · doi:10.3390/molecules19068039 · Cited by 24
Self-citationPrion Peptides Are Extremely Sensitive to Copper Induced Oxidative Stress
Dell’Acqua, S., Bacchella, C., Monzani, E., Nicolis, S., Natale, G. D., Rizzarelli, E., & Casella, L. (2017) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.7b01757 · Cited by 21
Self-citationChanges in nitric oxide metabolite levels in stimulated substantia nigra neurons
Zecca, L., Fariello, R. G., Galimberti, M., Racagni, G., & Ambrosini, A. (1997) · NeuroReport · doi:10.1097/00001756-199707070-00007 · Cited by 11
Self-citationWerner‐Allen, J. W., DuMond, J. F., Levine, R. L., & Bax, A. (2016) · Angewandte Chemie · doi:10.1002/ange.201600277 · Cited by 9
Synthesis of catecholamine conjugates with nitrogen-centered bionucleophiles
Siopa, F., Pereira, A. S., Ferreira, L. M., et al. (2012) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2012.05.002 · Cited by 7
Cited by
The Role of Oxidative Stress in Parkinson’s Disease
Chang, K.-H., & Chen, C.-M. (2020) · Antioxidants · doi:10.3390/antiox9070597 · Cited by 341
Dopamine in Parkinson's disease
Latif, S., Jahangeer, M., Maknoon Razia, D., Ashiq, M., Ghaffar, A., Akram, M., El Allam, A., Bouyahya, A., Garipova, L., Ali Shariati, M., et al. (2021) · Clinica Chimica Acta · doi:10.1016/j.cca.2021.08.009 · Cited by 340
Copper Dyshomeostasis in Neurodegenerative Diseases—Therapeutic Implications
Gromadzka, G., Tarnacka, B., Flaga, A., & Adamczyk, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239259 · Cited by 339
Role of dopamine in the pathophysiology of Parkinson’s disease
Zhou, Z. D., Yi, L. X., Wang, D. Q., Lim, T. M., & Tan, E. K. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00378-6 · Cited by 308
Gut liver brain axis in diseases: the implications for therapeutic interventions
Yan, M., Man, S., Sun, B., Ma, L., Guo, L., Huang, L., & Gao, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01673-4 · Cited by 287
Metadata
- Authors
- Monzani, E., Nicolis, S., Dell'Acqua, S., Capucciati, A., Bacchella, C., Zucca, F. A., Mosharov, E. V., Sulzer, D., Zecca, L., & Casella, L.
- Venue
- Angewandte Chemie International Edition
- Publisher
- Wiley
- Published
- 2019-03-21
- Volume
- 58
- Issue
- 20
- Pages
- 6512-6527
- ISSN
- 1433-7851 (ISSN-L)
- 1521-3773
- OpenAlex
- W2905515525
- Cited by
- 271
- References
- 176
- FWCI
- 13.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.